SouthernSun Asset Management, LLC, an investment management firm, released its “SouthernSun Small Cap Strategy” third quarter ...

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Ocugen (OCGN – Research Report) today and set a price target of ...

FOSTER CITY, Calif., November 12, 2024 -- ( BUSINESS WIRE )--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported ...

William Blair analyst Sami Corwin has maintained their bullish stance on TNYA stock, giving a Buy rating yesterday. Sami Corwin has given his ...

They have picked an area with ample growth potential: The overall telehealth market is expected to more than quintuple to $791 billion by 2034, according to research from Fortune Business Insights.

Compass Pathways is advancing pivotal trials to test psilocybin's impact on treatment-resistant depression. See why I rate ...

Nkarta faces competition from FATE's FT522, a CAR-NK cell therapy that might be used with reduced or no conditioning ...

Autolus Therapeutics’ (NASDAQ:AUTL) obe-cel has the potential to become a best-in-class cell therapy for the treatment of cancers. Industry analysts have a consensus Buy rating on the stock ...

U.S. Physical Therapy, Inc. (“USPH”) (NYSE ... USPH also has an industrial injury prevention business which provides onsite services for clients’ employees ...

Aliada's ALIA-1758, an antibody treatment, could be a best-in-class therapy, AbbVie said ... Reuters provides business, financial, national and international news to professionals via desktop ...

Q3 2024 Earnings Call Nov 08, 2024, 8:30 a.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants. Prepar ...

This growth will likely be driven by a less restrictive monetary policy and ongoing improvements in real wages, which could boost consumption and business investment. However, in the longer term ...